The review is expected to be completed by the end of the 2021-2022 financial year. The outcomes from the review will be considered by the Scottish Genomics Leadership Group (SGLG), chaired jointly by Professor David Crossman, Chief Scientist for Health for the Scottish Government, and Susan Buchanan, NSD Director, who are supporting the Scottish Government...